Sarepta and Biomarin resolve patent dispute with $35m licence
Biopharmaceutical company Sarepta Therapeutics and biotech firm Biomarin Pharmaceutical have settled a patent dispute and entered into a licence agreement.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 April 2022 BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.
26 April 2022 BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.
26 April 2022 BioMarin Pharmaceutical and MSD, have sued Aurobindo Pharmaceuticals for patent infringement in a dispute over the drug Kuvan, used to treat a rare genetic disorder.